Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195999 | 1.00 | POLB (0.49) | POLBCASP6L3MBTL1MEN1GAA | |
| SCHEMBL195906 | 0.88 | GABRA5 (0.61) | POLBCASP6L3MBTL1GABRA5 | |
| SCHEMBL195905 | 0.88 | GABRA5 (0.61) | POLBCASP6L3MBTL1GABRA5 | |
| SCHEMBL195442 | 0.85 | GABRA5 (0.63) | GABRA5 | |
| SCHEMBL195443 | 0.85 | GABRA5 (0.63) | GABRA5 | |
| SCHEMBL14796906 | 0.84 | GABRA5 (0.54) | GABRA5 | |
| SCHEMBL195454 | 0.84 | GABRA5 (0.64) | GABRA5 | |
| SCHEMBL195453 | 0.84 | GABRA5 (0.64) | GABRA5 | |
| SCHEMBL3403603 | 0.82 | GABRA5 (0.65) | GABRA5 | |
| SCHEMBL195455 | 0.82 | GABRA5 (0.65) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401271-B1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER AS GABA A ALPHA5 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | claimed |
| US-8389550-B2 | Isoxazoles / O-pyridines with ethyl and ethenyl linker | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| EP-2401271-A1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER AS GABA A ALPHA5 RECEPTOR INVERSE AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097368-A1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | claimed |
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | ROCHE PALO ALTO LLC | 2010-08-26 | — | — | US | claimed |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| EP-2575455-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | The Regents of the University of California (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2401271-B1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER AS GABA A ALPHA5 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-8389550-B2 | Isoxazoles / O-pyridines with ethyl and ethenyl linker | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2401271-A1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER AS GABA A ALPHA5 RECEPTOR INVERSE AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010097368-A1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | ROCHE PALO ALTO LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | GABRA5, GABRA1, GABRA4 | POLB 4558/4885CASP6 4540/4885L3MBTL1 4327/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | POLB 4627/4885CASP6 969/4885L3MBTL1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.